drugset / Trial / NCT07456046
A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.
NaSequentialOpen-labelTreatment
Summary
This is a first-in-human (FIH) multicenter, open-label, dose-escalation Phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of D3S-003 in participants with advanced KRAS p.G12D mutant solid tumors.
Timeline
- Start
- 2026-05-29
- Primary completion
- 2028-01-11
- Completion
- 2028-01-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | D3S-003 | Unknown | — | Oral |
Indications
No indication recorded.